Research progress on immune efficacy and safety of 13-valent pneumococcal polysaccharide conjugate vaccine in children with congenital heart disease

Abstract

Abstract: Children with congenital heart disease（CHD） are at high risk of developing severe pneumonia and death after being infected with Streptococcus pneumoniae. In recent years, research on the immune effect of 13-valent pneumococcal polysaccharide conjugate vaccine（PCV13） in children with CHD has attracted the attention of many medical experts. This article reviews the research progress on the immune effect and safety of PCV13 in CHD children by searching databases such as China National Knowledge Infrastructure（CNKI）, VIP, Wanfang, Pubmed, etc., providing reference for PCV13 vaccination in CHD children.

Key words: 13-valent pneumococcal polysaccharide conjugate vaccine, Congenital heart disease, Pneumococcal pneumonia, Immune efficacy, Safety

CLC Number:

R186

ZHANG Rui, CHENG Wanran, CHEN Linyan, WANG Weiping, FENG Yong, DENG Pengfei. Research progress on immune efficacy and safety of 13-valent pneumococcal polysaccharide conjugate vaccine in children with congenital heart disease. [J]OCCUPATION AND HEALTH, 2024, 40(11): 1581-1584.

References

[1] WALPERT A S,THOMAS I D,LOWE M J,et al.RSV prophylaxis guideline changes and outcomes in children with congenital heart disease[J].Congenit Heart Dis,2018,13(3):428-431.
[2] RAZZAGHI H,OSTER M,REEFHUIS J.Long-term outcomes in children with congenital heart disease:National health interview survey[J].J Pediatr,2015,166(1):119-124.
[3] WASSERMAN M,CHAPMAN R,LAPIDOT R,et al.Twenty-year public health impact of 7- and 13-valent pneumococcal conjugate vaccines in US Children[J].Emerg Infect Dis,2021,27(6):1627-1636.
[4] 赵德峰,胡权,熊燕,等.武汉地区健康婴幼儿肺炎链球菌携带率及血清型分布[J].现代预防医学,2012,39(9):2166-2168.
[5] 中华预防医学会.肺炎链球菌性疾病相关疫苗应用技术指南(2012版)[J].中华流行病学杂志,2012,33(11):1101-1110.
[6] WAHL B,O'BRIEN K L,GREENBAUM A,et al.Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines:Global,regional,and national estimates for 2000-15[J].Lancet Glob Health,2018,6(7):e744-e757.
[7] LAI X,WAHL B,YU W,et al.National,regional,and provincial disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type b in children in China:Modelled estimates for 2010-17[J].Lancet Reg Health West Pac,2022,22:100430.
[8] PELTON S I,WEYCKER D,FARKOUH R A,et al.Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine[J].Clin Infect Dis,2014,59(5):615-623.
[9] 李沁原,李媛媛,易茜,等.儿童侵袭性肺炎链球菌疾病临床特点及耐药性分析[J].中华实用儿科临床杂志,2020,35(8):586-589.
[10] GRANT C C,HARNDEN A R,JEWELL G,et al.Invasive pneumococcal disease in Oxford,1985-2001:A retrospective case series[J].Arch Dis Childhood,2003,88(8):712-714.
[11] 马冬雪,张慧娜,翟英菊,等.营养不良、先天性心脏病与儿童重症肺炎的关联性分析[J].临床肺科杂志,2018,23(5):883-886.
[12] 徐雷,陈蕾,王冲,等.儿童重症肺炎105例临床特征及高危因素分析[J].齐鲁医学杂志,2012,27(3):250-252.
[13] 崔金玲.探讨婴幼儿先天性心脏病并发肺炎死亡的危险因素[J].世界最新医学信息文摘,2017,17(55):258,260.
[14] MOHSIN S S,HAQUE A,SHAIKH A S,et al.Outcome of infants with unrepaired heart disease admitted to the pediatric intensive care unit:Single-center developing country perspective[J].Congenit Heart Dis,2014,9(2):116-121.
[15] 史淑芬,孙穆,梁卫兰,等.先心病患儿预防接种安全性探讨[J].首都公共卫生,2010,4(4):174-176.
[16] 陈伟敏,管咏梅,俞红云,等.先天性心脏病患儿疫苗接种的调查研究[J].中国心血管病研究,2021,19(7):644-649.
[17] MARTINÓN-TORRES F,CZAJKA H,CENTER K J,et al.13-valent pneumococcal conjugate vaccine(PCV13) in preterm versus term infants[J].Pediatrics,2015,135(4):e876-e886.
[18] 中华预防医学会,中华预防医学会疫苗与免疫分会.肺炎球菌性疾病免疫预防专家共识(2020版)[J].中国疫苗和免疫,2021,27(1):1-47.
[19] 李燕,安志杰,王华庆.6周龄开始13价肺炎球菌结合疫苗基础免疫免疫原性、安全性及效果分析[J].中国公共卫生,2018,34(11):1491-1495.
[20] BAXTER R,AUKES L,PELTON S I,et al.Impact of the 13-Valent pneumococcal conjugate vaccine on invasive pneumococcal disease after introduction into routine pediatric use[J].J Pediatric Infect Dis Soc,2020,10(2):141-150.
[21] HARBOE Z B,DALBY T,WEINBERGER D M,et al.Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcaldisease incidence and mortality[J].Clin Infect Dis,2014,59(8):1066-1073.
[22] WHO.Immunization dashboard-Global[EB/OL].(2023-08-20)[2023-07-17].https://immunizationdata.who.int/.
[23] VANDERKOOI O G,SCHEIFELE D W,GIRGENTI D,et al.Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada[J].Pediatr Infect Dis J,2012,31(1):72-77.
[24] 周凯,谢国锦,王晓卫,等.侵袭性肺炎链球菌病临床特征与血清型分布[J].中华医院感染学杂志,2015,25(15):3392-3394.
[25] LIANG Q,LI H,CHANG X,et al.A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old[J].Vaccine,2021,39(47):6947-6955.
[26] 刘维. 宁波市儿童13价肺炎球菌结合疫苗接种率和保护效果的初步调查[D].武汉:华中科技大学,2021.
[27] SOLÓRZANO-SANTOS F,ESPINOZA-GARCÍA L,AGUILAR-MARTÍNEZ G,et al.Pneumococcal conjugate vaccine and pneumonia prevention in children with congenital heart disease[J].Rev Invest Clin,2017,69(5):270-273.
[28] DEMCZUK W H B,MARTIN I,GRIFFITH A,et al.Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine,2010-2012[J].Can J Microbiol,2013,59(12):778-788.
[29] JACEK W,JERZY B,HENRYK S,et al.Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination[J].Vaccine,2015,33(14):1719-1725.
[30] DE ST M A,GRIJALVA C G,FONNESBECK C,et al.Racial and regional differences in rates of invasive pneumococcal disease[J].Pediatrics,2015,136(5):e1186-e1194.
[31] HUNG T,KOTECHA R S,BLYTH C C,et al.Immunogenicity and safety of single-dose,13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients[J].Cancer,2017,123(21):4215-4223.
[32] WANG W,LIANG Q,ZHU J,et al.Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants:A randomized,double blind phase Ⅲ clinical trial[J].Hum Vaccin Immunother,2022,18(1):2019498.
[33] GOLDBLATT D,SOUTHERN J,ANDREWS N J,et al.Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose(1+1) compared with two primary doses and a booster(2+1) in UK infants:A multicentre,parallel group randomised controlled trial[J].Lancet Infect Dis,2018,18(2):171-179.
[34] CHHATWAL J,SAPRU A,SUNDARAM B,et al.A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India[J].Vaccine,2021,39(37):5313-5317.
[35] DI LORENZO A,MARTINELLI A,BIANCHI F P,et al.The safety of pneumococcal vaccines at the time of sequential schedule:Data from surveillance of adverse events following 13-valent conjugated pneumococcal and 23-valent polysaccharidic pneumococcal vaccines in newborns and the elderly,in Puglia(Italy),2013-2020[J].Ann Ig,2023, 35(4):459-467.
[36] 胡昱,黄镇,汪颖,等.浙江省国产13价肺炎球菌多糖结合疫苗疑似预防接种异常反应监测分析[J].中华预防医学杂志,2022,56(11):1625-1629.
[37] 骆晓艳,高志刚,李永成,等.天津市6周龄-5岁儿童国产13价肺炎球菌多糖结合疫苗疑似预防接种异常反应主动和被动监测评价[J].中国疫苗和免疫,2022,28(5):591-594.
[38] 白云骅,李淑萍,丁舒,等.两种部位接种13价肺炎球菌多糖结合疫苗的安全性评价[J].中国生物制品学杂志,2019,32(6):678-682.
[39] 吴长初,刘金伟,丁自海.婴幼儿肌内注射部位的解剖学观测[J].解剖与临床,2007(6):380-382.
[40] 陈丽青,陆燕,张红梅,等.婴幼儿不同部位接种7价肺炎球菌结合疫苗不良反应发生情况比较及分析[J].中国初级卫生保健,2014, 28(4):52-54.
[41] LI M,JI C,ZENG Y,et al.Reasons of the delayed vaccination,recommendations and safety of vaccination in children with congenital heart disease in Zhejiang,China[J].Hum Vaccin Immunother,2021,17(7):2065-2071.
[42] 耿玲玲,胡伟军,陈艳妮,等.陕西省特殊健康状态儿童预防接种评估门诊心脏结构异常儿童预防接种研究[J].中国疫苗和免疫,2022, 28(1):88-93.